COVID-19Academic/ScientificBreaking news N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 April 1, 2021 N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
COVID-19Academic/ScientificBreaking news Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein April 1, 2021 Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
COVID-19Academic/ScientificBreaking news Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication April 1, 2021 Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
COVID-19Academic/ScientificBreaking news A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques April 1, 2021 A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
COVID-19Academic/ScientificBreaking news Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein April 1, 2021 Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
COVID-19Academic/ScientificBreaking news The first 12 months of COVID-19: a timeline of immunological insights April 1, 2021 The first 12 months of COVID-19: a timeline of immunological insights
COVID-19Academic/ScientificBreaking news The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue April 1, 2021 The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue
COVID-19Academic/ScientificBreaking news Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 April 1, 2021 Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
COVID-19Academic/ScientificBreaking news A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies April 1, 2021 A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
COVID-19Academic/ScientificBreaking news Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome April 1, 2021 Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome
COVID-19Academic/ScientificBreaking news Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19 April 1, 2021 Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19
COVID-19Academic/ScientificBreaking news Immunogenicity of the Ad26.COV2.S vaccine for COVID-19 April 1, 2021 Immunogenicity of the Ad26.COV2.S vaccine for COVID-19
COVID-19Academic/ScientificBreaking news Association of clinical, biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19 April 1, 2021 Association of clinical, biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19
COVID-19Academic/ScientificBreaking news Four-month clinical status of a cohort of patients after hospitalization for COVID-19 April 1, 2021 Four-month clinical status of a cohort of patients after hospitalization for COVID-19
COVID-19Academic/ScientificBreaking news EEG Abnormalities are Common in COVID-19 and are Associated with Outcomes April 1, 2021 EEG Abnormalities are Common in COVID-19 and are Associated with Outcomes